Heroin detoxification with buprenorphine on an inpatient psychiatric unit

Journal of Substance Abuse Treatment

Volumn 23, Issue 3, 2002, Pages 163-169

  DiPaula, Bethany A ^a,b   Schwartz, Robert ^c   Montoya, Ivan D ^d   Barrett, David ^e   Tang, Cecilia ^e  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b Walter P Carter Center   (United States)

^c FRIENDS RESEARCH INSTITUTE   (United States)

^d NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Buprenorphine; Detoxification; Heroin dependence; Psychiatric comorbidity; Psychiatric hospitalization

Indexed keywords

BUPRENORPHINE; DIAMORPHINE; DIPHENHYDRAMINE; FLUOXETINE; IBUPROFEN; MAGNESIUM HYDROXIDE; NORTRIPTYLINE; PARACETAMOL; PAROXETINE; PROCHLORPERAZINE; RISPERIDONE; TRAZODONE;

ADULT; ARTICLE; CLINICAL ARTICLE; COCAINE DEPENDENCE; DETOXIFICATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HEROIN DEPENDENCE; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; MALE; MENTAL HOSPITAL; MENTAL PATIENT; MOOD DISORDER; PRIORITY JOURNAL; SIDE EFFECT; SUBSTANCE ABUSE; TREATMENT OUTCOME; URBAN AREA;

ADULT; ANALGESICS, OPIOID; BALTIMORE; BUPRENORPHINE; COCAINE-RELATED DISORDERS; COMORBIDITY; EMERGENCY SERVICES, PSYCHIATRIC; FEMALE; HEROIN DEPENDENCE; HUMANS; MALE; MIDDLE AGED; MOOD DISORDERS; NARCOTIC ANTAGONISTS; PATIENT SATISFACTION; PILOT PROJECTS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 0036774497     PISSN: 07405472     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0740-5472(02)00244-1     Document Type: Article

References (21)

1. Amass L., Kamien J.B., Mikulich S.K. Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet. Drug and Alcohol Dependence. 58:2000;143-152.
2. Blennow G., Fergusson A., Medvedeo A. Buprenorphine as a new alternative for detoxification of heroin addicts. Laekartidningen. 97:2000;1830-1833.
3. Brooner R.K., King V.L., Kidorf M., Schmidt C.W., Bigelow G.E. Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Archives of General Psychiatry. 54(1):1997;71-80.
4. Cheskin L.J., Fudala P.J., Johnson R.E. A controlled comparison of buprenorphine and clonidine for acute detoxification from opioids. Drug and Alcohol Dependence. 36:1994;115-121.
5. Dixon L. Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophrenia Research. 35(Suppl):1999;93-100.
6. Dixon L., McNary S., Lehman A.F. Remission of substance use disorder among psychiatric inpatients with mental illness. American Journal of Psychiatry. 155:1998;239-243.
7. Fava M., Abraham M., Alpert J., Nierenberg A.A., Pava J.A., Rosenbaum J.F. Gender differences in Axis I comorbidity among depressed outpatients. Journal of Affective Disorders. 38:1996;129-133.
8. Gowing L., Ali R., White J. Opioid antagonists and adrenergic agonists for the management of opioid withdrawal. The Cochrane Database of Systematic Reviews. 2:2000;. CD002021.
9. Gowing L., Ali R., White J. Buprenorphine for the management of opioid withdrawal (Cochrane Review). The Cochrane Database of Systematic Reviews. 3:2000;. CD002025.
10. Kuhlman J.J., Lalani S., Magluilo J., Levine B., Darwin W.D. Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. Journal of Analytical Toxicology. 20(6):1996;369-378.
11. Lange W.R., Fudala P.J., Dax E.M., Johnson R.E. Safety and side-effects of buprenorphine in the clinical management of heroin addiction. Drug and Alcohol Dependence. 26:1990;19-28.
12. Liu Z.M., Cai Z.J., Wang X.P., Ge Y., Li C.M. Rapid detoxification of heroin dependence by buprenorphine. Acta Pharmacologica Sinica. 18(2):1997;112-114.
13. Montoya I.D., Svikis D., Marcus S.C., Suarez A., Tanielian T., Pincus H.A. Psychiatric care of patients with depression and comorbid substance use disorders. Journal of Clinical Psychiatry. 61:2000;698-705.
14. Nigam A.K., Ray R., Tripathi B.M. Buprenorphine in opiate withdrawal: a comparison with clonidine. Journal of Substance Abuse Treatment. 10:1993;391-394.
15. O'Connor P.G., Carroll K.M., Shi J.M., Schottenfeld R.S., Kosten T.R., Rounsaville B.J. Three methods of opioid detoxification in a primary care setting. A randomized trial. Annals of Internal Medicine. 127:1997;526-530.
16. Peachey J.E., Lei H. Assessment of opioid dependence with naloxone. British Journal of Addiction. 83:1988;193-201.
17. RachBeisel J., Scott J., Dixon L. Co-occurring severe mental illness and substance use disorders: a review of recent research. Psychiatric Services. 50:1999;1427-1434.
18. Strain E.C., Bigelow G.E., Liebson I.A., Stitzer M.L. Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial. Journal of the American Medical Association. 281:1999;1000-1005.
19. Umbricht A., Montoya I.D., Hoover D.R., Demuth K.L., Chiang C.T., Preston K.L. Naltrexone shortened opioid detoxification with buprenorphine. Drug and Alcohol Dependence. 56:1999;181-190.
20. Walsh S.L., Preston K.L., Stitzer M.L., Cone E.J., Bigelow G.E. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clinical Pharmacology & Therapeutics. 55:1994;569-580.
21. Wells K.B. Treatment research at the crossroads: the scientific interface of clinical trials and effectiveness research. American Journal of Psychiatry. 156(1):1999;5-10.